Discover recent advancements in near-infrared fluorescence imaging that have revolutionised lymph node tracing in cancers ...

Climate change is increasing the risk of urological diseases, including cancer and kidney conditions, while urological ...

"What is a tumor?" This is the fundamental question to answer if we want to treat cancer effectively. Our vision of cancer ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

EARLY-STAGE bladder cancer can be effectively diagnosed using unprocessed urine samples at the point of care, achieving 90% ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in the EU and the United Kingdom for Anktiva (nogapendekin alfa inbakicept) in ...

ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...

for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without ...

ImmunityBio achieved a 55% disease-free rate at 12 months for BCG-unresponsive NMIBC and plans an sBLA submission in 2025. NSCLC Phase 2b trial (N=86) showed a median overall survival of 14.1 ...